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Part A: ABSTRACT 
 
CYTOMEGALOVIRUS RETINITIS AT GROOTE SCHUUR 
HOSPITAL: CLINICAL MANAGEMENT AND OUTCOMES 
 
Lapere SRJ, Rice J 
University of Cape Town 
 
Objectives 
1. To review the clinical presentation, management and outcomes of patients 
who were diagnosed and treated for cytomegalovirus (CMV) retinitis at 
Groote Schuur Hospital over a 10 year period 
2. To review and compare the treatment protocols of thirteen public hospital 
centres in South Africa that treat patients for CMV retinitis 
 
Design & method 
This is a retrospective cohort study. A record review of 141 eyes in 91 patients 
diagnosed with and treated for CMV retinitis between 2003 and 2013 was performed. 
Additionally, a standard questionnaire was sent to thirteen public hospitals in South 
Africa that treat patients for CMV retinitis to determine current treatment protocols. 
 
At Groote Schuur Hospital, all cases of suspected CMV retinitis undergo a vitreous 
biopsy for polymerase chain reaction (PCR) confirmation. Treatment consists of 
weekly intravitreal ganciclovir injections until clinical resolution has taken place. 
Patients not on highly active anti-retroviral treatment (HAART) are referred for 
initiation of treatment. Ganciclovir treatment is continued until immune reconstitution 
has taken place. 
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Results 
All patients were PCR positive for CMV. The median age was 33.6 years (range 14-
58 years) and patients were followed up for a mean of 8.1 months (range 0-56 
months). Sixty percent of patients were female. Ninety-nine percent of patients were 
HIV positive and 73% were on HAART at presentation. Presenting CD4 counts 
ranged from 1 to 478 cells/mm3, with a mean of 58 cells/mm3. Presenting visual 
acuity ranged from Snellen acuity of 6/6 to no light perception.  
 
Fifty percent of patients had macular involvement on presentation and 48% had the 
margin of the optic disc involved. The number of injections ranged from 0 to 29 per 
eye, with an average of 4.9 injections per eye. Nineteen percent of patients had a final 
visual acuity of light perception or no light perception. Those that achieved a final 
visual acuity of hand movements or better had a mean final visual acuity of LogMAR 
1.05 (Snellen acuity 6/60). 
 
There was a significant association between the number of retinal quadrants involved 
and final visual outcome (p=0.009). Patients who were on HAART at the time of 
presentation had a better mean final visual acuity than those not on HAART 
(p=0.001). Macular involvement had a significant effect on visual outcome compared 
to those with uninvolved maculas (p<0.005). Presenting visual acuity strongly 
predicts final visual acuity - patients who presented with a visual acuity of 6/18 or 
better had a 4.6 times higher chance of obtaining a final visual acuity of 6/18 or better 
(p<0.005) at the end of follow up. Neither the presenting CD4 count nor the number 
of injections affected the final visual outcome. 
 
Twenty-two percent of patients developed retinal detachments. The number of retinal 
quadrants involved, CD4 count and presenting visual acuity had no statistically 
significant effect on retinal detachment rate. Forty-two percent of patients defaulted 
treatment or died during treatment. 
 
All centres in South Africa that responded to the survey treat CMV retinitis with 
intravitreal ganciclovir as the primary treatment. The differences in protocol are found 
in: diagnosing clinically or using PCR, intravitreal injection time interval and whether 
fundus photos or serial diagrams are used to assess treatment response. 
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Conclusion 
Independent risk factors that predict final visual outcome include presenting visual 
acuity, number of retinal quadrants involved, macular involvement and HAART 
treatment at presentation. Most centres in South Africa follow similar protocols for 
diagnosing and treating CMV retinitis. 
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Part B: PROTOCOL 
 
CYTOMEGALOVIRUS RETINITIS AT GROOTE SCHUUR 
HOSPITAL: CLINICAL MANAGEMENT AND OUTCOMES 
 
S Lapere Registrar:  Department of Ophthalmology 
Supervisor Dr J Rice: Consultant, Department of Ophthalmology 
  Groote Schuur Hospital 
 
Purpose 
The purpose of this study is to review the clinical presentation, management and 
outcomes of patients diagnosed and treated for cytomegalovirus retinitis at Groote 
Schuur Hospital. 
 
Background 
Cytomegalovirus (CMV) is a ubiquitous, large DNA member of the family 
Herpesviridae. It persists in the body like other Herpes viruses resulting in latency. It 
is the most common ocular opportunistic infection among patients with AIDS. It 
occurs with increasing frequency as the CD4 count drops below 100 cells/, with most 
patients having CD4 counts of less than 50 cells/mm3. Twenty to forty percent of 
patients with CD4 counts of <50 develop CMV retinitis. 
 
The hallmark of CMV retinitis is a necrotising, full thickness retinitis. It is 
characterised by a dense, white, well-demarcated, geographical area of confluent 
opacification often associated with retinal haemorrhages. There is a slow but 
relentless “bushfire-like” extension along the course of retinal vascular arcades that 
may involve the optic nerve head. Without treatment the entire retina may become 
involved. 
 
The two main principles of treatment of CMV retinitis are to improve the patient’s 
immune function and to use specific anti-CMV agents. Previous studies have 
investigated the effect of highly active antiretroviral therapy (HAART) on CMV 
retinitis.1,2 The incidence and recurrence rates have been shown to decrease as a result 
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of the restored immunity that HAART treatment provides. With the advent of 
HAART there has been a 75% reduction in the number of new cases of CMV 
retinitis.1 Maintenance treatment with anti-CMV agents is continued until immune 
reconstitution is achieved. Thereafter, CMV treatment can be stopped and HAART is 
continued lifelong. 
 
It has been shown that HAART alone can cause regression of small areas of CMV 
retinitis. However, because of the delay in recovery of immune function, HAART 
should not be used alone in the management of these patients. It typically takes 3 
months with a CD4 count of above 100 cells/mm3 to heal CMV retinitis.  
 
Current treatment regimes for the management of CMV retinitis include intravenous 
therapy (ganciclovir, foscarnet or cidofovir), oral therapy (ganciclovir or 
valganciclovir) and intravitreal therapy (ganciclovir injection, ganciclovir implant or 
foscarnet injection). Intravenous therapy requires lengthy inpatients admissions and 
can cause haematological abnormalities. Oral ganciclovir has very poor 
bioavailability (6%), while valganciclovir has better bioavailability (60%) but is an 
expensive drug. Intravitreal ganciclovir is the most effective drug for treating CMV 
retinitis, but does not protect against CMV in the fellow eye. 
 
There is no standardised protocol for the treatment of CMV retinitis in South Africa. 
A study done in Durban in 2003, in which patients received bi-weekly intravitreal 
injections of ganciclovir, showed promising results, with 51% of patients showing an 
improvement in vision, 15% unchanged and 34% deteriorating. However, in this 
study, only 16.6% of patients were on HAART.3  
 
In the above study, ganciclovir injections were administered twice weekly. A study 
done in 1996 found that the intravitreal concentration of ganciclovir after a single 
injection was above the ID50 for CMV (0.25-1.22 mg/l) after 7 days. This supports 
the use of a weekly injection for induction and maintenance therapy,4 which is 
currently practiced at Groote Schuur Hospital. 
 
At Groote Schuur Hospital, our current protocol is as follows: 
1. The diagnosis of CMV retinitis is made clinically. 
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2. Fundus photographs are taken for referencing purposes. 
3. The diagnosis is confirmed by obtaining a vitreous sample for polymerase 
chain reaction (PCR) testing at the time of the first intravitreal ganciclovir 
injection. 
4. Patients are offered HIV testing if their status is not known. 
5. Intravitreal ganciclovir injections are administered weekly until resolution 
occurs. 
6. Thereafter, patients are reviewed 2-weekly and discharged from the clinic 
when the ophthalmologist is satisfied that clinical resolution is maintained and 
the patient’s immune system has improved to a CD4 count of 
>100cells/microliter for 3 months. Patients who are not on HAART are 
referred to their ARV clinics so that HAART can be started as soon as 
possible. 
 
We plan to contact the ophthalmology consultants at the thirteen state hospital centres 
in South Africa that have the facilities to treat CMV retinitis to enquire on their eye 
unit’s protocols for the treatment of CMV retinitis. When we publish our findings, 
this will add a good discussion point as to whether treatment for CMV retinitis is 
standardised across all eye units in South Africa. We plan to contact the following 
centres: 
-­‐ Tygerberg Hospital 
-­‐ George Hospital 
-­‐ Port Elizabeth Hospital Complex 
-­‐ East London Hospital Complex 
-­‐ Umtata Hospital 
-­‐ Durban Hospital Complex 
-­‐ Pietermaritzburg Hospital 
-­‐ Bethlehem Hospital 
-­‐ Bloemfontein Hospital Complex 
-­‐ Johannesburg Hospital Complex 
-­‐ Pretoria Academic Hospital 
-­‐ Kimberley Hospital 
-­‐ Mankweng Hospital 
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Methodology 
Study design 
Retrospective cohort study. 
 
Study population 
All patients treated for cytomegalovirus retinitis at Groote Schuur Hospital from 1 
June 2003 to 1 June 2013 will be included in the study. Follow-up will be 
documented up to 3 months after the date of diagnosis. 
 
Recruitment 
The uveitis database (HREC reference R047/2014) will be used to identify the 
patients. 
 
Data collection 
The patients’ hospital folders will be accessed to collect relevant data.  No contact 
will be made with the patient. 
 
The following data will be collected from the database and folders: 
• Hospital number 
• Age  
• Gender 
• Date of diagnosis 
• Presenting visual acuity 
• Ocular signs 
o Vasculitis 
o Number of retinal quadrants involved 
o Macula involved 
o Vitritis  
• HIV status 
• CD4 count at diagnosis 
• Vitreous PCR results 
• Number of injections 
• Final visual acuity 
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• Co-infections (if any) 
• Complications 
o Retinal detachment 
o Infection (endophthalmitis) 
• Treatment given 
o Intravitreal ganciclovir only 
o Intravenous ganciclovir for those patients with systemic CMV 
 
Data analysis 
Microsoft Excel tables will be used to for data capturing.  Statistical significance 
related to continuous variables will be analysed using t-tests or Wilcoxon-Mann 
Whitney rank sum depending on the normality of the distribution of the data. 
Categorical variables will be analysed using the Chi-square test. Logistic regression 
models will be used to assess risk factors for outcomes in the multivariate analysis. 
 
Risks and benefits 
There will be no risk to the participants as this is a retrospective review of treatment 
which has already been administered. 
 
Benefits would include measuring the outcome of the treatment and comparing this to 
national and international literature. We would also be able to contribute to the 
current body of literature on the subject.The study was approved by the Human 
Research Ethics Committee of the University of Cape Town (HREC reference 
384/2014). 
 
Informed consent 
No consent will be obtained, as this is a retrospective folder review without any 
patient contact.   
 
Privacy and confidentiality 
Privacy and confidentiality of all data and results will be ensured. All data will be 
stored on a password protected computer. Hospital numbers will be used a patient 
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identification and no names will be stored in the database. Reporting will not include 
any form of patient identification. 
 
Reporting of findings 
Our aim would be to publish our results in an ophthalmology journal for peer review.  
We also aim to present our results at the annual Ophthalmological Society of South 
Africa congress. 
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Part C: LITERATURE REVIEW 
 
1. INTRODUCTION 
 
South Africa has  HIV epidemic in the world. In 2012, an estimated 6.1 million 
people were living with HIV, with 240,000 South Africans dying from AIDS-related 
illnesses.1 According to the Lancet ‘Health in South Africa Series’, South Africa has 
the largest antiretroviral treatment rollout programme in the world, with about 1.8 
million people estimated to be taken antiretrovirals by April 2011. This has assisted in 
raising the life expectancy to 60 years.2 The Lancet World Report states that South 
Africa now invests more than 1 billion annually to run its HIV and AIDS programs.3  
 
2. CYTOMEGALOVIRUS 
 
Cytomegalovirus (CMV) is ubiquitous, large DNA member of the family 
Herpesviridae. It receives its name from the typical enlargement of infected cells. 
Transmission can occur from exposure to infected saliva or urine, sexual contact, via 
an infected maternal carrier or from donor organs at the time of organ transplantation. 
 
CMV persists in the body like other Herpes viruses, resulting in latency. It is 
continually suppressed by cell-mediated immunity. In immunocompetent hosts, 
infection is usually asymptomatic, although some people may develop an influenza-
like syndrome characterized by malaise, myalgia, arthralgia, fever and chills. It is rare 
for people with normal immune systems to develop long-term sequelae. CMV is an 
opportunistic infection and and remains latent until the patient suffers from a 
significant local or systemic immunodeficiency. Immunocompromised patients suffer 
from decreased cell mediated immunity and may develop colitis, pneumonitis, 
hepatitis and CMV retinitis. In the past, immunosuppression associated with organ 
transplantation and chemotherapy was the most common cause of CMV retinitis. In 
the current era, the increasing number of occurrences of patients with AIDS has led to 
a marked increase in the number of occurrences of CMV retinitis. 
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CMV retinitis is thought to reach the eye via the blood stream, although the 
possibility of reactivation of latent virus has not been ruled out. Evidence of 
haematogenous spread includes the fact that one eye frequently develops retinitis 
several months before the other, and that new foci of retinitis can appear in an already 
infected eye.4  
 
CMV retinitis begins as small, white retinal infiltrates which, if seen early, may 
resemble a large cottonwool spot. Two types of clinical appearance may be seen: The 
first is a perivascular fluffy white lesion with many scattered retinal haemorrhages.4 
There is a slow but relentless “bushfire-like” extension along the course of retinal 
vascular arcades that may involve the optic nerve head. Without treatment the entire 
retina becomes involved within a few months.(5) (Figure 1)  
 
 
 
 
 
 
 
Figure 1: Extension and retinal necrosis along the arcades 
 
Another manifestation is a more granular appearing lesion that has few associated 
haemorrhages and often has a central area of clearing, with atrophic retina and 
stippled retinal pigment epithelium. (Figure 2) 
 
 
 
 
 
 
 
 
 
Figure 2: Granular indolent appearance 
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CMV is diagnosed clinically in most patients as it has a characteristic fundoscopic 
appearance.5 In cases where there may be co-existing infection with other organisms, 
or where the clinical diagnosis is not clear, polymerase chain reaction (PCR) has a 
sensitivity of 95% and a specificity of 99%. PCR based anaysis of vitreous samples in 
the diagnosis of infectious retinitis is well supported.6  
 
3. HIV/AIDS and CMV RETINITIS 
 
CMV retinitis is the most common cause of vision loss in patients with AIDS.7 In a 
British based post-mortem series of HIV patients in the pre-HAART era, 72% of 
patients had chronic uveal inflammation, with 38% being caused by CMV.8 CMV 
retinitis is an opportunistic and late manifestation of the HIV disease, usually 
associated with T-lymphocyte CD4 counts of <50 cells/mm3.9 Kestly documented the 
epidemiology of CMV retinitis in Africa and found the prevalence to vary 0 to 8.5% 
in patients with acquired immunodeficiency syndrome.10  
 
A study by Hodge et al. assessed clinical risk factors for CMV retinitis in AIDS 
patients. In patients who are not on HAART it is estimated that the time from 
development of AIDS to manifestation of CMV retinitis is 9 to 18 months. Among the 
clinical risk factors studied, cotton wool spots and floaters or flashing lights were 
found to be important predictors of CMV retinitis. Cotton wool spots represent an 
area of damaged retinal microcirculation and hence an avenue whereby CMV can 
gain access to the retina. They also found nonocular CMV infection to be a very 
strong predictor of CMV retinitis.11  
 
4. HAART and CMV RETINITIS 
 
Before HAART, treatment of CMV retinitis consisted of lifelong treatment. Mortality 
rates due to HIV were high. In a study done in 1992 which studied the difference in 
mortality of patients treated with ganciclovir and those treated with foscarnet, the 
median survival was 8.5 months in the ganciclovir group and 12.6 months in foscarnet 
group. Relapses were common within weeks of discontinuing maintenance therapy.12 
HAART was introduced in 1996. It was originally defined as two nucleoside reverse 
transcriptase inhibitors (NRTI’s) combined with a protease inhibitor (PI). In 2004, the 
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definition was expanded by the Kaiser panel to include a PI, a non-nucleoside reverse 
transcriptase inhibitor and one of the NRTI’s. In a study of 1632 AIDS patients with a 
history of severe immune deficiency, it was found that HAART led to a substantial 
decrease in the incidence of CMV retinitis when compared to other studies (5.60/100 
person-years).13 This Longitudinal Study of the Ocular Complications of AIDS had an 
oversampling of CMV retinitis due to the groups interest in ocular complications, and 
this data is best interpreted as the upper limit on the incidence of CMV retinitis in 
patients who are on HAART. The actual incidence may be even lower.13 A separate 
study showed that there has been a 75% reduction in the number of new cases of 
CMV retinitis since the advent of HAART.14  
 
Further benefits of HAART include a reduction in the number of hospital admission 
and improvement in quality and length of life. A study by Douglas et al showed that 
patients with immune reconstitution could safely have their anti-CMV maintenance 
therapy discontinued. In this study, there were no relapses.15 The United States 
Department of Health and Human Services guidelines for the management of 
opportunistic infections in patients with AIDS recommend discontinuing anti-CMV 
therapy if the CD4+ T cells have increased to a level of >100 cells/for 3 to 6 months. 
A follow up study done supported these guidelines, and showed that discontinuing 
CMV therapy after immune recovery did not increase the risk of poor outcomes. Poor 
outcomes were defined as shortened survival or worsened course of retinitis.16  
 
Patients not on antiretroviral medication require workup and commencement of this . 
For HAART-failure patients, changing medication should be considered. Some 
infectious disease specialists may consider delaying the commencement of HAART 
in patients with opportunistic infections to minimize the risk of immune recovery 
uveitis. 
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5. TREATMENT OF CMV RETINITIS 
 
The principles of treatment of CMV retinitis are to improve the patient’s immune 
function and treat the infection with anti-CMV compounds.  include intravitreal 
injections of ganciclovir or foscarnet, intravitreal ganciclovir implants, intravenous 
medications (ganciclovir, foscarnet or cidofovir) or oral valganciclovir.  
 
Intravenous therapy 
Intravenous drugs require admission with venous access and daily therapy, which 
significantly impacts on quality of life, as immune reconstitution may take several 
months. Patients require a peripherally-insterted central catheter (PIC) line to allow 
atraumatic, intravenous access. Catheter-related sepsis remains an important 
complication and can occur in up to 12% of patients.17 Ganciclovir causes 
haematologic abnormalities (anaemia, neutropenia and thrombocytopenia) and may 
produce long term reproductive complications.18 Foscarnet is highly nephrotoxic and 
must be  administered carefully to patients with renal disease. Patients require 
adequate hydration and frequent monitoring of creatinine levels. Cidofovir is rarely 
used as long-term therapy as it causes severe renal toxicity. 
 
Oral therapy 
Oral ganciclovir was introduced in 1994 in an attempt to reduce costs, eliminate the 
inconvenience of admitting patients for intravenous infusions and to reduce the rate of 
catheter-related sepsis. The bioavailability was only 6% to 9%, so patients could not 
achieve plasma concentrations sufficient for induction therapy.17 Valganciclovir is the 
prodrug of ganciclovir. Its bioavailability is 60% and it can be used for both induction 
and maintenance therapy.19 It is well tolerated, with the most common side effects 
being neutropenia, anaemia, diarrhoea, nausea and vomiting. 
 
Intravitreal therapy 
Intravitreal ganciclovir was first investigated in animal models in 1985. It was 
initially used in patients who had severe adverse reactions to systemic ganciclovir. 
The pharmacodynamics were studied by Henry et al. in 1986(20) Lopez-Cortex et al. 
compared intravitreal ganciclovir with intravitreal foscarnet and found the that 
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intravitreal ganciclovir had a better pharmacokinetic profile. They supported the 
administration of the injection twice per week.21  
 
Initial suggested doses of intravitreal ganciclovir were 200mcg in 0.1ml.20 Morlet et 
al used 2mg in 0.1ml and found that the concentration of ganciclovir was 143.8mg/l at 
24 hours and 23.4mg/l at 72 hours. The mean half life was 18.8 hours. The calculated 
mean at seven days was 0.6mg/l. The intravitreal concentration achieved with this 
high dose therapy remained above the ID50 for CMV (0.25-1.22mg/l) for up to 7 days 
and they found that the drug was not likely to accumulate.22 This supports our 
protocol, which is the use of a weekly injection as induction and maintenance. 
 
The sustained-release intravitreal ganciclovir implant releases 1 microgram of 
ganciclovir per hour for 8 months. It is inserted through the pars plana and has shown 
to be highly eficacious against CMV retinitis, but is also very costly. 
 
Young et al. compared intravitreal ganciclovir alone with systemic ganciclovir. The 
results of this study strongly support the use of intravitreal ganciclovir alone, which is 
the current management strategy at Groote Shuur Hospital. They found a lower 
relapse rate in the intravitreal group (7% vs 56%) as well as more patients 
maintaining vision of 20/40 or better in the intravitreal group (85% vs 59%). 
 
6. DISCONTINUING ANTI-CMV TREATMENT 
 
In the absence of immune reconstitution, discontinuing anti-CMV treatment is not an 
option. Douglas et al. looked at retinitis progression in patient with CMV retinitis in 
the era of HAART. They found that the CD4+ T-cell count at enrollment was directly 
associated with the rate of retinitis progression (0.27/person year for patients with 
CD4+ T-cell of <50 vs 0.02/person year for patients with a CD=T-cell of >200, 
p<0.01). The decision to stop anti-CMV therapy depends upon many factors, 
including rising CD4+ T-lymphocyte counts, decreasing systemic HIV viral load, 
duration of HAART and inactivity of CMV lesions. Among patients with immune 
reconstitution to levels considered safe to discontinue anti-CMV therapy (>100 
cells/microliter), this study found that the rate of retinitis progression in patients with 
CD4+ T-cell counts of 100 to 199 cells/microliter  was 0.06/person year and in 
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patients with CD4+ T-cell counts of >200 cells/microliter, the rate was 0.02/person 
year. They concluded that the rate of retinitis progression in the HAART era is greatly 
reduced from that of the pre-HAART era, but the rate of progression was not zero.14  
 
Zambarakji et al. looked at the relationshiop between CD4 cell counts and CMV 
retinitis progression in 1292 patiens who were started on HAART. Sixty-six percent 
of patients developed CMV retinitis. They found that the proportion of patients with 
CD4 cell counts of <50 cells /decreased in response to HAART and the rate of change 
was greatest between 1 and 3 months after commencing treatment. HAART 
considerably reduced the rate of CMV retinitis adverse events, from 0.35 per 100 
patient days at risk, to 0.14. From a clinical standpoint, there were only 5 patients who 
developed adverse events during the second year of follow up and none during the 
third year, indicating significant immunorestoration beyond 12-18 months for all 
patients.23  
 
From the literature review of stopping anti-CMV treatment, there appears to be no 
absolute CD4 T-cell count value at which immune reconstitution occurs. It has been 
clearly shown that HAART significantly reduces the rate of CMV retinitis 
progression, but both clinical and CD4 T-cell count monitoring are required as some 
patients get recurrences depsite high CD4 T-cell counts. There are no strict guidelines 
for discharging patients and discontinuing monitoring altogether – this monitoring 
appears to be at the discretion of the treating physician, centre and resources 
available.  
 
The United States Public Health Service provided guidelines in 1999 to suggest 
discontinuing anti-CMV therapy after patients with quiescent retinitis achieve 
sustained immune recovery. Immune recovery was deficed as having CD4+ T-cell 
counts of 100 cells/or more for at least 2 or more consecutive visits at least 6 months 
apart.24  
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7. COMPLICATIONS 
 
Jennifer et al. studied 494 eyes of 379 patients with CMV retinitis on HAART to 
determine the common causes of visual acuity loss in these patients. Involvement of  
the posterior pole accounted for visual acuity loss of 20/50 or worse in half of the 
patients. Cataract accounted for 14.5% of visual loss and retinitis related retinal 
detachment accounted for 16.7% of visual loss. They concluded that zone 1 
involvement and retinal detachment remain the most common causes of visual acuity 
loss in patients with CMV retinitis.25 Yen et al. looked at risk factors for developing 
retinal detachments in patients with CMV retinitis and found bilateral disease and 
lesion size to be the strongest predictors.26  
 
8. CONCLUSION 
 
CMV retinitis in HIV positive patients is a sight-threatening opportunistic infection 
which requires aggressive and continuous treatment to preserve visual function. 
Intravitreal ganciclovir remains the most cost effective, available method of 
controlling CMV retinitis. Anti-CMV therapy needs to be continued until immune 
reconstitution has taken place. 
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1. ABSTRACT 
 
Objectives 
1. To review the clinical presentation, management and outcomes of patients 
who were diagnosed and treated for cytomegalovirus (CMV) retinitis at 
Groote Schuur Hospital over a 10 year period 
2. To review and compare the treatment protocols of thirteen public hospital 
centres in South Africa that treat patients for CMV retinitis 
 
Design & method 
This is a retrospective cohort study. A record review of 141 eyes in 91 patients 
diagnosed with and treated for CMV retinitis between 2003 and 2013 was performed. 
Additionally, a standard questionnaire was sent to thirteen public hospitals in South 
Africa that treat patients for CMV retinitis to determine current treatment protocols. 
 
At Groote Schuur Hospital, all cases of suspected CMV retinitis undergo a vitreous 
biopsy for polymerase chain reaction (PCR) confirmation. Treatment consists of 
weekly intravitreal ganciclovir injections until clinical resolution has taken place. 
Patients not on highly active anti-retroviral treatment (HAART) are referred for 
initiation of treatment. Ganciclovir treatment is continued until immune reconstitution 
has taken place. 
 
Results 
All patients were PCR positive for CMV. The median age was 33.6 years (range 14-
58 years) and patients were followed up for a mean of 8.1 months (range 0-56 
months). Sixty percent of patients were female. Ninety-nine percent of patients were 
HIV positive and 73% were on HAART at presentation. Presenting CD4 counts 
ranged from 1 to 478 cells/mm3, with a mean of 58 cells/mm3. Presenting visual 
acuity ranged from Snellen acuity of 6/6 to no light perception.  
 
Fifty percent of patients had macular involvement on presentation and 48% had the 
margin of the optic disc involved. The number of injections ranged from 0 to 29 per 
eye, with an average of 4.9 injections per eye. Nineteen percent of patients had a final 
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visual acuity of light perception or no light perception. Those that achieved a final 
visual acuity of hand movements or better had a mean final visual acuity of LogMAR 
1.05 (Snellen acuity 6/60). 
 
There was a significant association between the number of retinal quadrants involved 
and final visual outcome (p=0.009). Patients who were on HAART at the time of 
presentation had a better mean final visual acuity than those not on HAART 
(p=0.001). Macular involvement had a significant effect on visual outcome compared 
to those with uninvolved maculas (p<0.005). Presenting visual acuity strongly 
predicts final visual acuity - patients who presented with a visual acuity of 6/18 or 
better had a 4.6 times higher chance of obtaining a final visual acuity of 6/18 or better 
(p<0.005) at the end of follow up. Neither the presenting CD4 count nor the number 
of injections affected the final visual outcome. 
 
Twenty-two percent of patients developed retinal detachments. The number of retinal 
quadrants involved, CD4 count and presenting visual acuity had no statistically 
significant effect on retinal detachment rate. Forty-two percent of patients defaulted 
treatment or died during treatment. 
 
All centres in South Africa that responded to the survey treat CMV retinitis with 
intravitreal ganciclovir as the primary treatment. The differences in protocol are found 
in: diagnosing clinically or using PCR, intravitreal injection time interval and whether 
fundus photos or serial diagrams are used to assess treatment response. 
 
Conclusion 
Independent risk factors that predict final visual outcome include presenting visual 
acuity, number of retinal quadrants involved, macular involvement and HAART 
treatment at presentation. Most centres in South Africa follow similar protocols for 
diagnosing and treating CMV retinitis. 
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2. INTRODUCTION 
 
Cytomegalovirus (CMV) is a ubiquitous, large DNA member of the family 
Herpesviridae. It persists in the body like other Herpes viruses resulting in latency. It 
is the most common ocular opportunistic infection among patients with AIDS.1 It 
occurs with increasing frequency as the CD4 count drops below 100 cells/mm3, with 
most patients having CD4 counts of less than 50 cells/mm3.2 Twenty to forty percent 
of patients with CD4 counts of <50 cells/mm3 develop CMV retinitis. 
 
The hallmark of CMV retinitis is a necrotising, full thickness retinitis. It is 
characterised by a dense, white, well-demarcated, geographical area of confluent 
opacification often associated with retinal haemorrhages. There are two types of 
clinical appearance. The first is a slow but relentless “bushfire-like” extension along 
the course of retinal vascular arcades that may involve the optic nerve head. Without 
treatment the entire retina becomes involved within a few months. The second is a 
more granular appearing lesion that has few associated haemorrhages and often has a 
central area of clearing, with atrophic retina and stippled retinal pigment epithelium. 
 
The principles of treatment of CMV retinitis are to improve the patient’s immune 
function and to use specific anti-CMV agents. Many studies have investigated the 
effect of highly active antiretroviral therapy (HAART) on CMV retinitis.3 The 
incidence and recurrence rates have been shown to decrease as a result of the restored 
immunity that HAART treatment provides. With the advent of HAART there has 
been a 75% reduction in the number of new cases of CMV retinitis.4  
 
It has been shown that HAART alone can cause regression of small areas of CMV 
retinitis. It typically takes 3 months with a CD4 count of above 100 cells/mm3 to heal 
CMV retinitis. Because of the delay in the recovery of the immune function, HAART 
should not be used alone in the management of these patients. 
 
Alternate treatments regimes for the management of CMV retinitis exist, and these 
include more expensive agents such as valganciclovir (oral), foscarnate (intravenous 
or intravitreal) and cidofovir (intravenous or intravitreal). 
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There is no standardised protocol for the treatment of CMV retinitis in South Africa. 
A study done in Durban in 2003, in which patients received bi-weekly intravitreal 
injections of ganciclovir, showed promising results, with 51% of patients showing an 
improvement in vision, 15% unchanged and 34% deteriorating. However, in this 
study, only 16.6% of patients were on HAART.5 In this study, ganciclovir injections 
were administered twice weekly. A previous study in 1996 found that the intravitreal 
concentration of ganciclovir was above the ID50 for CMV (0.25-1.22 mg/l) after 7 
days and the drug is not likely to accumulate. This supports the use of a weekly 
injection as induction and maintenance6, which is what is currently practiced at 
Groote Schuur Hospital. 
 
At Groote Schuur Hospital, our current protocol is as follows: 
1. The diagnosis of CMV retinitis is made clinically. 
2. Fundus photographs are taken for referencing purposes. 
3. The diagnosis is confirmed by obtaining a vitreous sample for polymerase 
chain reaction (PCR) testing at the time of the first intravitreal ganciclovir 
injection. 
4. Patients are offered HIV testing if their status is not known. 
5. Intravitreal ganciclovir injections are administered weekly until resolution 
occurs. 
6. Thereafter, patients are reviewed 2-weekly and discharged from the clinic 
when the ophthalmologist is satisfied that clinical resolution is maintained 
and the patient’s immune system has improved to a CD4 count of >100 
cells/mm3 for 3 months. Patients who are not on HAART are referred to 
their ARV clinics so that HAART can be started as soon as possible. 
 
In this study, we examined risk factors which could possible predict a poorer or more 
favourable outcome in patients with CMV retinitis. We also assessed whether centres 
in South Africa have a standardised approach to induction, maintenance and 
discontinuation of treatment of patients with CMV retinitis. Current treatment 
strategies across these centres were compared. 
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3. METHODS 
 
This is a retrospective cohort study. A record review of 141 eyes in 91 patients 
diagnosed with and treated for CMV retinitis between 2003 and 2013 was performed. 
Patients were identified from the uveitis database (HREC reference R047/2014). Only 
patients with PCR proven CMV retinitis were included. Patients with CMV retinitis 
who had co-infection with another organism (E.g. syphilis, herpes simpex) were 
excluded. Patients who had poor or no follow-up and patients in which poor fundal 
view precluded accurate assessment were excluded.  
 
Data was captured on a single data capture sheet for each patient, and transferred to 
an exel spread sheet where is was analysed using Stata 10.0.7 Statistical significance 
related to continuous variables will be analysed using t-tests or Wilcoxon-Mann 
Whitney rank sum depending on the normality of the distribution of the data. 
Categorical variables will be analysed using the Chi-square test. Logistic regression 
models will be used to assess risk factors for outcomes in the multivariate analysis. 
 
Visual acuity was captured as Snellen visual acuity, and converted to LogMAR.8 For 
our statistical analysis, vision of ‘light perception’ and ‘no light perception’ were not 
used in the calculation of mean acuity but were included in categorical analyses. 
 
A good visual outcome was defined as final visual acuity of 6/12 (LogMAR 0.3) or 
better (Category 1). A moderate visual outcome was defined as 6/18 to 6/36 
(LogMAR 0.5 to 0.8)  (Category 2), with a poor visual outome being 6/60 (LogMAR 
1.00) or worse (Category 3). 
 
A standard questionnaire was sent to thirteen public hospital centres in South Africa 
that treat patients for CMV retinitis (Appendix B). 
 
The study was approved by the Human Research Ethics Committee of the University 
of Cape Town (HREC reference 384/2014). 
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4. RESULTS 
 
One hundred and forty one eyes of 91 patients were included in the study. Twenty 
seven patients were excluded from the study (10 did not have PCR proven CMV 
retinitis, 6 had files that were not traceable, 6 had co-infection in the eye with other 
organisms and 5 did not return after an initial visit). Fifty patients had bilateral disease 
and 41 patients had unilateral disease. The median age was 33.6 years (range 14-58 
years) and patients were followed up for a mean of 8.1 months (range 0-56 months). 
Sixty percent of patients were female. Ninety-nine percent of patients were HIV 
positive and 73% were on HAART at the time of presentation. Forty-two percent of 
patients defaulted treatment or died during treatment. 
 
Presenting visual acuity ranged from 6/6 (LogMAR 0.0) to no light perception. Fifty 
five percent of eyes had a presenting Snellen visual acuity of 6/60 (LogMAR 1.00) or 
worse. The presenting acuities are summarised in Table 1. 
 
 
Table 1: Presenting visual acuity 
 
Presenting CD4 counts ranged from 1 cell/mm3 to 478 cells/mm3, with a mean of 58 
cells/mm3. We found presenting CD4 count to have no effect on final visual acuity. 
Using the Wilcoxon-Mann-Whitney test, there was no statistically significant 
difference in the median final visual acuity when comparing patients who presented 
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with a CD4 of less than 50 cells/mm3 to those with a CD4 of more than 50 cells/mm3 
(p=0.89). 
 
The number of injections ranged from 0 to 29 per patients, with an average of 4.9 
injections per patient. There was no association between the number of injections 
administered and the final visual outcome. (p=0.17, Fishers extract) 
 
Fifty percent of patients had macular involvement on presentation and 48% had the 
margin of the optic disc involved. Patients with macular involvement on presentation 
had poorer visual outcomes (p<0.05) compared with those in whom the macula was 
spared. 
 
Sixty percent of patients presented with retinal vasculitis, and 71% had vitritis of 
varying degrees on presentation. There was a significant association between the 
number of retinal quadrants involved and final visual outcome. (p=0.009, Pearson 
Chai Square) (Table 2)  
 
 
 
Table 2: Pearson Chi Square analysis showing 
the correlation between retinal quadrants 
involved and final visual outcome 
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Seventy three percent of patients were on HAART at presentation. Patients who were 
on HAART at the time of presentation had a better final visual acuity than those not 
on HAART. Two-sample Wilcoxon rank-sum test showed a p-value of 0.001. 
However, there was no statistically significant difference when comparing the number 
of injections needed to achieve disease resolution in patients on HAART and patients 
who were not on HAART (p=1.88). 
 
Twenty-two percent of patients developed retinal detachments. Chi Square analysis 
releaved no statistically significant relationship between presenting CD4 count and 
the development of a retinal detachment (p=0.499). Unlike final visual acuity, the 
number of retinal quadrants involved did not affect the development of a retinal 
detachment (p=0.40, Chi Square). Presenting visual acuity could also not predict the 
rate of retinal detachment (p=0.58). 
 
Presenting visual acuity was a strong predictor of final visual acuity (Chi Square 
p<0.01). (Table 3) 
 
 
 
 
 
 
 
Linear regression model analysis showed that patients who presented with a visual 
acuity of 6/18 or better had a 4.6 times higher chance of obtaining a final visual acuity 
of 6/18 or better (p<0.01). 
Table 3: Relationship between presenting 
and final visual acuity 
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Questionnaires were sent to thirteen public health centres in South Africa that treat 
CMV retinitis. Responses were received from nine centres. All centres that 
participated use intravitreal ganciclovir as the primary treatment of CMV retinitis. 
Five centres diagnose CMV retinitis by clinical appearance alone, two centres used 
PCR only in cases with an atypical presentation, and two centres perform PCR 
vitreous taps routinely on all suspected cases. 
 
There was considerable variability with intravitreal ganciclovir injection intervals 
between centres. Two centres inject patients weekly, three centres inject patients 
twice per week until injections are stopped (they do not decrease the intervals to 
weekly), three centres start injections at intervals of twice per week, and decrease the 
intervals to weekly either according to set protocols or titrated to CD4 count. One 
centre injects all patients on an ‘as needed’ basis only. 
 
Four centres have ‘set regimes’ for the minimum number of injections and intervals, 
which they will administer to all patients before titrating the number and interval of 
injections to the clinical response. Five centres do not have these ‘set regimes’ and 
will re-evaluate patients at each visit. 
 
Five centres rely on fundus drawings for comparison when deciding whether a repeat 
injection is necessary, while four centres compare fundus photographs on each visit. 
 
Seven centres do not perform prophylactic argon demarcation laser on any patients, 
while two centres perform laser on selected patients only. 
 
Six centres have fixed criteria for stopping anti-CMV treatment. They all vary slightly 
and none of them strictly adhere to the United States Public Health Service guidelines 
of 1999 for discontinuing anti-CMV therapy. Three centres do not have fixed criteria, 
with decisions being made on a patient-by-patient basis. 
 
Seven centres monitor patients’ CD4 counts as part of their treatment, while two 
centres do not. All centres refer patients who are not on HAART to their local clinics 
for workup and commencement of HAART. 
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5. DISCUSSION 
 
This retrospective cohort study describes the spectrum of presenting features, clinical 
course and prognostic factors of patients presenting with CMV retinitis as Groote 
Schuur Hospital. 
 
Independent risk factors associated with better final visual outcome include good 
presenting visual acuity, fewer retinal quadrants involved, absence of macular 
involvement and HAART treatment at presentation. Presenting CD4 count and the 
number of injections received were not predictive of final visual outcome. 
 
Our study found that patients who were on HAART at the time of presentation had a 
better mean final visual acuity that those not on HAART (p<0.01). Several other 
studies have shown that the introduction of HAART has led to a substantial decrease 
in the incidence and course of CMV retinitis9,4, which would explain why patients on 
HAART had better final visual acuities. A separate study showed that HAART 
considerably reduced the rate of CMV retinitis adverse events, from 0.35 per 100 
patient days at risk, to 0.14.10  
 
In a study of 494 eyes of 379 CMV retinitis patients, 16.7% of patients were found 
found to have a retinitis-related retinal detachment.11 Twenty-two percent of patients 
in our study developed retinal detachments. Forty percent of patients in this study11 
had macular involvement at baseline, compared to the 50% in our study. Yen et al. 
looked at risk factors for developing retinal detachments in patients with CMV 
retinitis and found bilateral disease and lesion size to be the strongest predictors.12  
Macular involvement understandably has a significant effect on visual outcome when 
compared to uninvolved maculas (p<0.05). Prophylactic argon retinal 
photocoagulation has been successful in anectodal reports and small case series13 but 
there is not uniformity among the centres in South Africa about treating patients 
prophylactically with laser. 
 
The decision to stop anti-CMV therapy depends upon many factors, including rising 
CD4+ T-lymphocyte counts, decreasing systemic HIV viral load, duration of HAART 
and inactivity of CMV lesions. There is a discrepancy amongst the centres in South 
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Africa regarding the decision to stop therapy. 
 
Forty two percent of patients defaulted treatment or died during treatment. Patients 
with CMV retinitis usually have severe immunosuppression and are susceptible to a 
wide variety of other opportunistic infections. In our patient population, transport 
difficulties and social stigma are further barriers that may prevent optimal follow up. 
This has affected our results, as only 58% of patients had adequate follow-up until the 
treating ophthalmologst had discharged them. Another limitation is the retrospective 
nature of our study.  Injection dates were often missed. Different clinicians were 
examining patients at each visit, but this was overcome by using photos rather than 
drawings for comparison.  
 
There is no ‘national protocol’ for initiation, continuation and discontinuation of 
treatment for CMV retinitis. The only similarities between centres are the use of 
intravitreal ganciclovir as the mainstay of treatment, as well as vague similarities 
when discontinuing treatment. The most striking differences are diagnostic methods 
(clinical vs PCR), intravitreal injection time interval, monitoring of CD4 counts and 
criteria for repeat injections.  
 
A protocol for all centres would certainly be useful, as our countries healthcare 
system is resource-limited. 
 
Our suggested protocol for treating CMV retinitis is as follows: 
1. The diagnosis of CMV retinitis can be made clinically. If there is any doubt, 
PCR confirmation should be used. 
2. Fundus photographs should be taken for referencing and comparison purposes. 
If a centre does not have fundus photos available, the same clinician should 
preferably examine the patient on subsequent visits. 
3. Patients should be offered HIV testing if their status is not known. 
4. Intravitreal ganciclovir injections should be administered weekly until clinical 
resolution occurs. 
5. Once clinical resolution has occurred, patients can be reviewed with 
increasing frequency between visits.  
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6. Patients can be discharged from the clinic when the ophthalmologist is 
satisfied that clinical resolution is maintained and the patient’s immune system 
has improved to a CD4 count of >100 cells/mm3 for 3 months. 
 
Our study found that patients who are more likely to have favourable visual outcomes 
are those who present with better visual acuities, have less retinal quadrants involved, 
do not have macular involvement and are on HAART at presentation. The converse is 
true for poor visual outcomes. Most centres in South Africa follow similar protocols 
for diagnosing and treating CMV retinitis, but a standardised protocol is yet to be 
adopted by all centres. 
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Part E: APPENDICES 
Appendix A: Data capture form with coding 
 
  Coding 
Folder No.   
Age               
Gender  0=female 1=male 
Eye  0=right 1=left 
HIV status 
 
 .=unknown 
0=negative 
1=positive 
Date of diagnosis   
Presenting visual acuity  Convert to LogMAR 
CD4 count on presentation 
 
  
Macula involved  0=no 1=yes 
Optic disc involved 
 
 0=no 
1=yes 
Number of quadrants 
involved 
 1, 2, 3, 4 
 
Vasculitis  0=no 1=yes 
Vitritis  0=no 1=yes 
On HAART at presentation  0=no 1=yes 
CMV PCR result 
 
 .=unkown/not done 
0=negative 1=positive 
Dates of injections   
Number of top-up injections 
after initial phase 
  
Was prophylactic laser 
performed 
  
CD4 count on discharge   
Did fellow eye become 
involved 
 0=no 
1=yes 
Final visual acuity  Convert to LogMAR 
Treatment for systemic 
ganciclovir 
 0=no 
1=yes 
Complications 
 
 .=retinal detachment 
0=infection 
1=other (specify) 
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Appendix B: Questionnaire: CMV retinitis treatment protocol 
 
Dear Doctor, 
 
I am doing my MMed dissertation on the clinical management and outcomes of CMV 
retinitis at Groote Schuur Hospital. 
 
There is currently no standardised protocol that is being used nationwide. I would like 
to gather the management protocols of all the units in South Africa that treat CMV 
retinitis, and compare these. As part of the discussion for my dissertation, I would like 
to propose a standardised treatment regime that can be used by all units. 
 
I would appreciate it if you would take a few minutes of your time to complete the 
questionnaire below. 
 
Thank you 
Dr Steven Lapere 
 
1. How do you diagnose CMV retinitis at your unit? 
a. Clinically only 
b. PCR 
c. Both clinically and PCR 
d. Clinically, but we use PCR in cases with an atypical presentation 
e. Other (specify) 
 
Answer_________________________ 
 
2. How do you treat CMV retinitis at your unit? 
a. Intravitreal ganciclovir injections 
b. Intravenous ganciclovir 
c. Intravenous acyclovir 
d. Other (specify) 
 
Answer_________________________ 
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3. If you use intravitreal ganciclovir, how often are the injections given? 
a. Twice a week 
b. Weekly 
c. Every 2nd week 
d. As needed 
e. Other (specify) 
 
Answer_________________________ 
 
4. Do you have a set regime for a minimum number of injections, or are patients re-
evaluated at each visit? 
a. Set regime (specify how many and interval) 
 
b. Re-evaluated at each visit 
 
Answer_________________________ 
 
 
5. How often are patients asked to return for follow-up visits? 
a. Twice a week 
b. Weekly 
c. Every second week 
d. Monthly 
e. As needed 
f. Other (specify) 
 
Answer_________________________ 
 
 
6. What criteria do you use to decide if a repeat injection is necessary? 
a. Clinically – compared to previous drawing 
b. Clinically – compared to previous fundus photograph 
 
Answer_________________________ 
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7. Do you perform prophylactic demarcation laser? 
a. Yes – all patients 
b. Yes – selected patients only 
c. No 
 
Answer_________________________ 
 
 
8. Do you have fixed criteria for stopping treatment? What are these? 
 
Answer_________________________ 
 
 
9. Are patients’ CD4 counts monitored as part of the treatment? 
 
Answer_________________________ 
 
 
10. How is it used if it is monitored? 
 
Answer_________________________ 
 
11. When patients are not on ARV’s, are they referred for commencement of ARV’s? 
 
Answer_________________________ 
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Appendix C: Department of Surgery Research Committee approval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“OUR MISSION is to be an outstanding teaching and research university, 
educating for life and addressing the challenges facing our society.” 
 
  UNIVERSITY OF CAPE TOWN 
 
               Department of Surgery 
       
Departmental Research Committee 
Professor Anwar Suleman Mall 
J-45 Room Old Main Building, Groote Schuur Hospital,  
Observatory 7925, South Africa 
                     Tel (021) 406 6168/6232/6227 Fax (021) 448 6461 
Email: Anwar.Mall@uct.ac.za 
 
 
 
25th February 2014 
 
Dr S Lapere  
Department of Surgery 
Division of Ohpphthalmology      
Groote Schuur Hospital 
University of Cape Town 
  
 
Dear Dr Lapere, 
 
 
RE:  PROJECT 2014/019 
 
  
PROJECT TITLE:  Cytomegalovirus retinitis at Groote Schuur Hospital: Clinical 
management and outcomes 
 
         
The above proposal was reviewed by the Department of Surgery Research Committee and I am pleased 
to inform you that the committee approved the study. 
 
Please use the above project number in all future correspondence. 
 
 
 
Yours sincerely 
 
 
PROFESSOR ANWAR S MALL 
CHAIRMAN: RESEARCH COMMITTEE 
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Appendix D: Human Research Ethics Committee approval 
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